Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.
Phase 1
Recruiting
- Conditions
- Preeclampsia during pregnancyTherapeutic area: Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]Therapeutic area: Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
- Registration Number
- CTIS2022-500933-10-00
- Lead Sponsor
- Centre Hospitalier Universitaire De Toulouse
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1164
Inclusion Criteria
Nulliparous women aged 18 years or more, Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor, Singleton pregnancy, Evolutive pregnancy between 9 and 14 weeks of gestation, Women affiliated to a French Social Security Insurance or equivalent social protection, Written informed consent
Exclusion Criteria
Major fetal abnormality, Regular treatment with aspirin (including antiphospholipid syndrome), Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia), Women protected by law., Women included in another interventional study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method